Perturbation of Rb, p53, and Brca1 or Brca2 Cooperate in Inducing Metastatic Serous Epithelial Ovarian Cancer

被引:95
|
作者
Szabova, Ludmila [1 ]
Yin, Chaoying [4 ]
Bupp, Sujata [1 ]
Guerin, Theresa M. [1 ]
Schlomer, Jerome J. [1 ]
Householder, Deborah B. [1 ]
Baran, Maureen L. [1 ]
Yi, Ming [2 ]
Song, Yurong [3 ,4 ]
Sun, Wenping [2 ]
McDunn, Jonathan E. [5 ]
Martin, Philip L. [1 ]
Van Dyke, Terry [1 ,3 ,4 ]
Difilippantonio, Simone [1 ]
机构
[1] NCI Federick, Ctr Adv Preclin Res, SAIC, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA
[2] NCI Federick, Adv Biomed Comp Ctr, SAIC, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA
[3] NCI Frederick, Mouse Canc Genet Program, Frederick, MD USA
[4] Univ N Carolina, Dept Genet, Chapel Hill, NC USA
[5] Metabolon Inc, Durham, NC USA
关键词
MOUSE MODEL; CONDITIONAL INACTIVATION; FALLOPIAN-TUBE; PERITONEAL MESOTHELIOMA; PAPILLARY CARCINOMA; DISTANT METASTASES; MUTATIONS; INDUCTION; WOMEN; P130;
D O I
10.1158/0008-5472.CAN-11-3834
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The majority of human high-grade serous epithelial ovarian cancer (SEOC) is characterized by frequent mutations in p53 and alterations in the RB and FOXM1 pathways. A subset of human SEOC harbors a combination of germline and somatic mutations as well as epigenetic dysfunction for BRCA1/2. Using Cre-conditional alleles and intrabursal induction by Cre-expressing adenovirus in genetically engineered mice, we analyzed the roles of pathway perturbations in epithelial ovarian cancer initiation and progression. Inactivation of RB-mediated tumor suppression induced surface epithelial proliferation with progression to stage I carcinoma. Additional biallelic inactivation and/or missense p53 mutation in the presence or absence of Brca1/2 caused progression to stage IV disease. As in human SEOC, mice developed peritoneal carcinomatosis, ascites, and distant metastases. Unbiased gene expression and metabolomic profiling confirmed that Rb, p53, and Brca1/2-triple mutant tumors aligned with human SEOC, and not with other intraperitoneal cancers. Together, our findings provide a novel resource for evaluating disease etiology and biomarkers, therapeutic evaluation, and improved imaging strategies in epithelial ovarian cancer. Cancer Res; 72(16); 4141-53. (C) 2012 AACR.
引用
收藏
页码:4141 / 4153
页数:13
相关论文
共 50 条
  • [1] Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos
    Ludwig, T
    Chapman, DL
    Papaioannou, VE
    Efstratiadis, A
    GENES & DEVELOPMENT, 1997, 11 (10) : 1226 - 1241
  • [2] Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer
    Wenham, RM
    Schildkraut, JM
    McLean, K
    Calingaert, B
    Bentley, RC
    Marks, J
    Berchuck, A
    CLINICAL CANCER RESEARCH, 2003, 9 (12) : 4396 - 4403
  • [3] Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer
    Liu, Guoyan
    Yang, Da
    Sun, Yan
    Shmulevich, Ilya
    Xue, Fengxia
    Sood, Anil K.
    Zhang, Wei
    PHARMACOGENOMICS, 2012, 13 (13) : 1523 - 1535
  • [4] Inactivation of BRCA1 and BRCA2 in ovarian cancer
    Hilton, JL
    Geisler, JP
    Rathe, JA
    Hattermann-Zogg, MA
    DeYoung, B
    Buller, RE
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (18): : 1396 - 1406
  • [5] The Contribution of BRCA1 and BRCA2 to Ovarian Cancer
    Ramus, Susan J.
    Gayther, Simon A.
    MOLECULAR ONCOLOGY, 2009, 3 (02) : 138 - 150
  • [6] BRCA1 and BRCA2 Mutations in Ovarian Cancer
    Buerkle, Bernd
    Tempfer, Clemens
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (04): : 359 - 359
  • [7] Breast cancer in young women: prevalence of LOH at p53, BRCA1 and BRCA2
    SM Johnson
    JA Shaw
    RA Walker
    Breast Cancer Research, 2 (Suppl 1)
  • [8] Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and P53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers
    Tair Kontorovich
    Yoram Cohen
    Uri Nir
    Eitan Friedman
    Breast Cancer Research and Treatment, 2009, 116 : 195 - 200
  • [9] Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and P53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers
    Kontorovich, Tair
    Cohen, Yoram
    Nir, Uri
    Friedman, Eitan
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 116 (01) : 195 - 200
  • [10] Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations
    Zweemer, RP
    Shaw, PA
    Verheijen, RMH
    Ryan, A
    Berchuck, A
    Ponder, BAJ
    Risch, H
    McLaughlin, JR
    Narod, SA
    Menko, FH
    Kenemans, P
    Jacobs, IJ
    JOURNAL OF CLINICAL PATHOLOGY, 1999, 52 (05) : 372 - 375